

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

June 2011

Vol. 39, No. 6

CONTENTS

SHORT COMMUNICATIONS

Role of Intestinal Cytochrome P450 (P450) in Modulating the Bioavailability of Oral Lovastatin: Insights from Studies on the Intestinal Epithelium-Specific P450 Reductase Knockout Mouse. *Yi Zhu, Jaime D'Agostino, and Qing-Yu Zhang* **939**

Cytochrome P450 2S1 is Reduced by NADPH-Cytochrome P450 Reductase. *Yi Xiao, Raku Shinkyo, and F. Peter Guengerich* **944**

The Tissue-Specific Toxicity of Methimazole in the Mouse Olfactory Mucosa Is Partly Mediated through Target-Tissue Metabolic Activation by CYP2A5. *Fang Xie, Xin Zhou, Mary Beth Genter, Melissa Behr, Jun Gu, and Xinxin Ding* **947**

ARTICLES

Absorption, Distribution, Metabolism, and Excretion of [¹⁴C]GDC-0449 (Vismodegib), an Orally Active Hedgehog Pathway Inhibitor, in Rats and Dogs: A Unique Metabolic Pathway via Pyridine Ring Opening. *Qin Yue, Yung-Hsiang Chen, Teresa Mulder, Alan Deese, Ryan Takahashi, Patrick J. Rudewicz, Mark Reynolds, Eric Solon, Cornelis E. C. A. Hop, Harvey Wong, and S. Cyrus Khojasteh* **952**

Suppression of Cytochrome P450 Reductase (POR) Expression in Hepatoma Cells Replicates the Hepatic Lipidosis Observed in Hepatic POR-Null Mice. *Todd D. Porter, Subhashis Banerjee, Elzbieta I. Stolarczyk, and Ling Zou* **966**

Substituted Imidazole of 5-Fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates Cytochrome P450 2D6 by Protein Ad-
duction. *Leslie D. Nagy, Catherine S. Mocny,*

Laura E. Diffenderfer, David J. Hsi, Brendan F. Butler, Evan J. Arthur, Kyle J. Fletke, Jairam R. Palamanda, Amin A. Nomeir, and Laura Lowe Furge **974**

Quantitative Time-Lapse Imaging-Based Analysis of Drug-Drug Interaction Mediated by Hepatobiliary Transporter, Multidrug Resistance-Associated Protein 2, in Sandwich-Cultured Rat Hepatocytes. *Takeo Nakanishi, Yuta Shibue, Yoko Fukuyama, Kenji Yoshida, Hajime Fukuda, Yoshiyuki Shirasaka, and Ikumi Tamai* **984**

Alteration of Hepatic but Not Renal Transporter Expression in Diet-Induced Obese Mice. *Vijay R. More and Angela L. Slitt* **992**

ATP-Binding Cassette Transporter Expression in Human Placenta as a Function of Pregnancy Condition. *Cifford W. Mason, Irina A. Buhimschi, Catalin S. Buhimschi, Yafeng Dong, Carl P. Weiner, and Peter W. Swaan* **1000**

Prediction of Human Renal Clearance from Preclinical Species for a Diverse Set of Drugs that Exhibit Both Active Secretion and Net Reabsorption. *Stuart W. Paine, Karelle Ménochet, Rebecca Denton, Dermot F. McGinnity, and Robert J. Riley* **1008**

Studies on the Metabolism and Biological Activity of the Epimers of Sulindac. *David Brunell, Daphna Sagher, Shailaja Kesaraju, Nathan Brot, and Herbert Weissbach* **1014**

Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib. *Hideo Takakusa, Michelle D. Wahlin, Chunsheng Zhao, Kelsey L. Hanson, Lee Sun New, Eric Chun Yong Chan, and Sidney D. Nelson* **1022**

Continued on next page

- [S] Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments. *Takao Watanabe, Hiroyuki Kusuhara, Tomoko Watanabe, Yasuyuki Debori, Kazuya Maeda, Tsunenori Kondo, Hideki Nakayama, Shigeru Horita, Brian W. Ogilvie, Andrew Parkinson, Zhuohan Hu, and Yuichi Sugiyama* **1031**
- [S] CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs. *Alfred Zimmerman, Markus Trunzer, and Bernard Faller* . . . **1039**
- Influence of Non-Steroidal Anti-Inflammatory Drugs on Organic Anion Transporting Polypeptide (OATP) 1B1- and OATP1B3-Mediated Drug Transport. *Juergen Kindla, Fabian Müller, Maren Mieth, Martin F. Fromm, and Jörg König* **1047**
- A Refined Cytochrome P450 IC₅₀ Shift Assay for Reliably Identifying CYP3A Time-Dependent Inhibitors. *Ping Li, Chuang Lu, Suresh K. Balani, and Liang-Shang Gan* **1054**
- Identification of Amiodarone Metabolites in Human Bile by Ultraperformance Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry. *Pan Deng, Tiangeng You, Xiaoyan Chen, Tao Yuan, Haihua Huang, and Dafang Zhong* **1058**
- Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir. *Brian J. Kirby, Ann C. Collier, Evan D. Kharsch, Dale Whittington, Kenneth E. Thummel, and Jashvant D. Unadkat* **1070**
- [S] Pharmacokinetics and Metabolism in Rats, Dogs, and Monkeys of the Cathepsin K Inhibitor Odanacatib: Demethylation of a Methylsulfonyl Moiety as a Major Metabolic Pathway. *Kelem Kassahun, W. Cameron Black, Deborah Nicoll-Griffith, Ian McIntosh, Nathalie Chauret, Stephen Day, Elizabeth Rosenberg, and Kenneth Koeplinger* **1079**
- [S] Pharmacokinetics and Hepatic Uptake of Eltrombopag, a Novel Platelet-Increasing Agent. *Kazuya Takeuchi, Tomoko Sugiura, Saki Umeda, Kazuki Matsubara, Masato Horikawa, Noritaka Nakamichi, David L. Silver, Norihisa Ishiwata, and Yukio Kato* **1088**
- Role of Organic Anion-Transporting Polypeptides for Cellular Mesalazine (5-Aminosalicylic Acid) Uptake. *Jörg König, Hartmut Glaeser, Markus Keiser, Kathrin Mandery, Ulrich Klotz, and Martin F. Fromm* **1097**
- Pharmacokinetics of the Monohydroxy Derivative of Oxcarbazepine and Its Enantiomers after a Single Intravenous Dose Given as Racemate Compared with a Single Oral Dose of Oxcarbazepine. *G. Flesch, C. Czendlik, D. Renard, and P. Lloyd* . . . **1103**
- ERRATUM**
- Correction to “Disposition and Metabolism of [¹⁴C]SB-649868, an Orexin 1 and 2 Receptor Antagonist, in Humans”. **1111**

[S] Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: A whole-body autoradiogram of the radioactivity distribution in female Long-Evans rats. See the article by Yue et al. on page 952 of this issue.